Currently, five EGFR TKIs are approved for the treatment of EGFR mutation-positive NSCLC: the first-generation reversible EGFR TKIs, gefitinib and erlotinib; the second-generation irreversible ErbB family blockers, afatinib and dacomitinib, and the third-generation wild-type sparing irreversible EGFR TKI, osimertinib [4–6]. Here, EGFR is linked to non-small cell lung carcinoma.